Grifols (GRFS) Long-Term Deferred Tax (2010 - 2025)
Grifols (GRFS) reported Long-Term Deferred Tax of $484.2 million for Q4 2025, up 32.5% on a YoY basis from $365.5 million in Q4 2024, and up 32.5% quarter-over-quarter from $365.5 million in Q4 2024.
Grifols (GRFS) Long-Term Deferred Tax (2010 - 2025) Analysis & Trends
Grifols has reported Long-Term Deferred Tax for 16 years, with the latest figure at $484.2 million in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Deferred Tax rose 32.5% year-over-year to $484.2 million; the trailing twelve-month figure through Dec 2025 stood at $484.2 million (up 32.5% YoY), and the FY2025 full-year result was $484.2 million, up 32.5% from the prior year.
- Long-Term Deferred Tax for Q4 2025 stood at $484.2 million, up from $365.5 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $484.2 million in Q4 2025, with the low at $174.5 million in Q4 2021.
- Historically, Long-Term Deferred Tax has averaged $305.2 million across 5 years, with a median of $323.1 million in 2023.
- Annual changes were most pronounced in 2021 — Long-Term Deferred Tax dropped 2.4% — and 2023, when it surged 81.06%.
- Grifols' Long-Term Deferred Tax stood at $174.5 million in 2021, then advanced by 2.29% to $178.5 million in 2022, then jumped by 81.06% to $323.1 million in 2023, then climbed by 13.1% to $365.5 million in 2024, then jumped by 32.5% to $484.2 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $484.2 million (Q4 2025), $365.5 million (Q4 2024), and $323.1 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 484.24 Mn |
| Dec 31, 2024 | 365.46 Mn |
| Dec 31, 2023 | 323.14 Mn |
| Dec 31, 2022 | 178.46 Mn |
| Dec 31, 2021 | 174.46 Mn |
| Dec 31, 2020 | 178.75 Mn |
| Dec 31, 2019 | 136.17 Mn |
| Dec 31, 2018 | 128.45 Mn |
| Jun 30, 2018 | 80.03 Mn |
| Dec 31, 2017 | 77.90 Mn |
| Jun 30, 2017 | 85.92 Mn |
| Dec 31, 2016 | 72.58 Mn |
| Sep 30, 2016 | 76.38 Mn |
| Jun 30, 2016 | 74.38 Mn |
| Dec 31, 2015 | 73.21 Mn |
| Sep 30, 2015 | 74.84 Mn |
| Jun 30, 2015 | 79,576.80 |
| Mar 31, 2015 | 92.69 Mn |
| Dec 31, 2014 | 103.04 Mn |
| Dec 31, 2013 | 47.10 Mn |